Public Joint-Stock Company "Pharmsynthez" reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was RUB 379.67 million compared to RUB 438.33 million a year ago. Net loss was RUB 207.49 million compared to RUB 697.55 million a year ago.

Basic loss per share from continuing operations was RUB 0.69 compared to RUB 2.32 a year ago. Diluted loss per share from continuing operations was RUB 0.69 compared to RUB 2.32 a year ago.